Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

The stock's fall snapped a four-day winning streak.

Three Motley Fool contributors believe they've identified fantastic dividend stocks to buy and hold for the next decade. Here's why they chose Abbott Laboratories ( ABT -1.00%), AbbVie ( ABBV 2.86%), ...

The stock exceeded the S&P 500 ... The investment community will be paying close attention to the earnings performance of Pfizer in its upcoming release. The company is slated to reveal its ...

Pfizer (PFE) stock is lower in Tuesday's session even ... pipeline," said Pfizer CEO Dr. Albert Bourla in a statement. "Our performance through the first three quarters of the year is the result ...

Pfizer's stock declined over 50% due to reduced sales ... The remarkable improvement was driven by the strong performance of Pfizer's core portfolio, particularly its drugs that treat cancer ...

Let’s understand the company’s strengths and weaknesses to better analyze how to play PFE’s stock in the post-earnings scenario. Sales of PFE’s COVID Products Decline With the end of the ...